Watch List for Traders: Transocean Ltd., Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ), Vale S.A. (NYSE:VALE)

Endo International plc (NASDAQ:ENDP) shares decreased -0.44% in last trading session and ended the day at $50.22. ENDP Gross Margin is 43.60% and its has a return on assets of -9.10%. Endo International plc (NASDAQ:ENDP) quarterly performance is -15.47%.

Endo Pharmaceuticals Inc., a subsidiary of Endo International plc (Nasdaq: ENDP), announced the availability of BELBUCA™ (buprenorphine) buccal film, the first and only buprenorphine formulation developed with a dissolving film that is absorbed through the inner lining of the cheek for chronic pain management. BELBUCA™, distributed and promoted by Endo, is now available nationwide.

Vericel Corporation (NASDAQ:VCEL) ended the last trading day at $2.02. Company weekly volatility is calculated as 8.39% and price to cash ratio as 2.57. Vericel Corporation (NASDAQ:VCEL) showed a weekly performance of -2.42%.

Vericel Corporation (NASDAQ: VCEL) announced that the U.S. Food and Drug Administration has approved the Company’s Humanitarian Device Exemption (HDE) supplement for Epicel (cultured epidermal autografts) to revise the labeled indications of use to specifically include pediatric patients and to add pediatric labeling. The revised product label also specifies that the probable benefit of Epicel, mainly related to survival, was demonstrated in two Epicel clinical experience databases and a randomized, controlled, independent physician-sponsored study comparing outcomes in patients with severe burns treated with Epicel and standard care compared to standard care alone.

On 23 February, Transocean Ltd. (NYSE:RIG) shares decreased -3.28% and was closed at $8.54. RIG EPS growth in last 5 year was -20.40%. Transocean Ltd. (NYSE:RIG) year to date (YTD) performance is -31.02%.

Transocean Ltd. (NYSE: RIG) announced that the company has received a notice of early termination from Esso Exploration Angola (Block 15) Limited for the ultra-deepwater semisubmersible GSF Development Driller I. The rig’s drilling contract is expected to end in May 2016 with the demobilization completed in June 2016. In accordance with the terms of this contract, the company will not receive a payment compensating it for the remaining contract term.

Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) shares decreased -2.81% in last trading session and ended the day at $121.92. JAZZ Gross Margin is 91.80% and its has a return on assets of 9.80%. Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) quarterly performance is -15.94%.

Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q4 EPS of $2.60, in-line with the analyst estimate of $2.60. Revenue for the quarter came in at $340.9 million versus the consensus estimate of $349.83 million. GUIDANCE: Jazz Pharmaceuticals sees FY2016 EPS of $10.90-$11.30, versus the consensus of $11.42. Jazz Pharmaceuticals sees FY2016 revenue of $1.490-1.550 billion, versus the consensus of $1.54 billion.

Vale S.A. (NYSE:VALE) caters to the Basic Materials space. It has a net profit margin of -12.00% and weekly performance is 12.27%. On the last day of trading company shares ended up at $3.11. Vale S.A. (NYSE:VALE) distance from 50-day simple moving average (SMA50) is 11.92%.

Vale SA (NYSE:VALE) released its 2015 production report, commenting that it posted annual and quarterly production records for iron ore, pellets, nickel, copper, cobalt and gold. The result pushed full-year 2015 output to 345.9-million tonnes, another record, helping to maintain Vale’s place as the world’s largest producer of the steelmaking ingredient. It did, however, beat Vale’s target of 340-million tonnes for the year.